{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:05:40Z","timestamp":1774418740078,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10147-026-02978-4","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:27:27Z","timestamp":1770384447000},"page":"666-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of first-line combination chemotherapy in older patients with unresectable advanced gastric cancer: a retrospective study"],"prefix":"10.1007","volume":"31","author":[{"given":"Ryuya","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko M.","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7477-4071","authenticated-orcid":false,"given":"Koji","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2978_CR1","unstructured":"National Cancer Registry (Ministry of Health, Labour and Welfare) (2025) Tabulated by Cancer Information Service, National Cancer Center, Japan. https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html. Accessed 3 Aug 2025."},{"key":"2978_CR2","unstructured":"National Cancer Institute Surveillance, Epidemiology and End Results Program, Cancer Stat Facts (2025) Stomach cancer. http:\/\/r.cancer.gov\/statfacts\/html\/stomach.html. Accessed 3 Aug 2025."},{"key":"2978_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12029-021-00797-6","volume":"54","author":"R Yamamoto","year":"2023","unstructured":"Yamamoto R, Honda M, Kawamura H et al (2023) Clinical features and survival of young adults with Stage IV gastric cancer: a Japanese population-based study. J Gastrointest Cancer 54:56\u201361. https:\/\/doi.org\/10.1007\/s12029-021-00797-6","journal-title":"J Gastrointest Cancer"},{"key":"2978_CR4","doi-asserted-by":"publisher","first-page":"101770","DOI":"10.1016\/j.canep.2020.101770","volume":"67","author":"D Lokanatha","year":"2020","unstructured":"Lokanatha D, Hassan SA, Jacob LA et al (2020) Socioeconomic and administrative factors associated with treatment delay of esophageal and gastric carcinoma: prospective study from a tertiary care centre in a developing country. Cancer Epidemiol 67:101770. https:\/\/doi.org\/10.1016\/j.canep.2020.101770","journal-title":"Cancer Epidemiol"},{"key":"2978_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/2050640620917804","volume":"8","author":"NF van Erp","year":"2020","unstructured":"van Erp NF, Helsper CW, Slottje P et al (2020) Time to diagnosis of symptomatic gastric and oesophageal cancer in the Netherlands: where is the room for improvement? United Eur Gastroenterol J 8:607\u2013620. https:\/\/doi.org\/10.1177\/2050640620917804","journal-title":"United Eur Gastroenterol J"},{"key":"2978_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association (2023) Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer 26:1\u201325. https:\/\/doi.org\/10.1007\/s10120-022-01331-8","journal-title":"Gastric Cancer"},{"key":"2978_CR7","unstructured":"National Cancer Institute (2025) Stomach cancer treatment. https:\/\/www.cancer.gov\/types\/stomach\/treatment#chemotherapy. Accessed 3 Aug 2025."},{"key":"2978_CR8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S et al (2022) Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1005\u20131020. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004","journal-title":"Ann Oncol"},{"key":"2978_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1200\/JCO.2003.04.130","volume":"21","author":"A Ohtsu","year":"2003","unstructured":"Ohtsu A, Shimada Y, Shirao K et al (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54\u201359. https:\/\/doi.org\/10.1200\/JCO.2003.04.130","journal-title":"J Clin Oncol"},{"key":"2978_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063\u20131069. https:\/\/doi.org\/10.1016\/S1470-2045(09)70259-1","journal-title":"Lancet Oncol"},{"key":"2978_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215\u2013221. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4","journal-title":"Lancet Oncol"},{"key":"2978_CR12","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.4143\/crt.2023.333","volume":"55","author":"KW Lee","year":"2023","unstructured":"Lee KW, Zang DY, Ryu MH et al (2023) A phase 3 randomized clinical trial to compare efficacy and safety between combination therapy and monotherapy in elderly patients with advanced gastric cancer (KCSG ST13-10). Cancer Res Treat 55:1250\u20131260. https:\/\/doi.org\/10.4143\/crt.2023.333","journal-title":"Cancer Res Treat"},{"key":"2978_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jgo.2017.01.002","volume":"8","author":"IG Hwang","year":"2017","unstructured":"Hwang IG, Ji JH, Kang JH et al (2017) A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol 8:170\u2013175. https:\/\/doi.org\/10.1016\/j.jgo.2017.01.002","journal-title":"J Geriatr Oncol"},{"key":"2978_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s10120-014-0405-8","volume":"18","author":"DS Sun","year":"2015","unstructured":"Sun DS, Jeon EK, Won HS et al (2015) Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer. Gastric Cancer 18:644\u2013652. https:\/\/doi.org\/10.1007\/s10120-014-0405-8","journal-title":"Gastric Cancer"},{"key":"2978_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s10120-018-0797-y","volume":"21","author":"A Makiyama","year":"2018","unstructured":"Makiyama A, Kunieda K, Noguchi M et al (2018) First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study. Gastric Cancer 21:792\u2013801. https:\/\/doi.org\/10.1007\/s10120-018-0797-y","journal-title":"Gastric Cancer"},{"key":"2978_CR16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2188\/jea.je20090066","volume":"20","author":"S Kimura","year":"2010","unstructured":"Kimura S, Sato T, Ikeda S et al (2010) Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol 20:413\u2013419. https:\/\/doi.org\/10.2188\/jea.je20090066","journal-title":"J Epidemiol"},{"key":"2978_CR17","unstructured":"JMDC inc (2025) JMDC claims database. https:\/\/www.jmdc.co.jp\/en\/jmdc-claims-database\/. Accessed 3 Aug 2025."},{"key":"2978_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.mayocp.2019.12.004","volume":"95","author":"M Takeuchi","year":"2020","unstructured":"Takeuchi M, Ogura M, Minoura T et al (2020) Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus other classes of glucose-lowering medications on renal outcome in type 2 diabetes. Mayo Clin Proc 95:265\u2013273. https:\/\/doi.org\/10.1016\/j.mayocp.2019.12.004","journal-title":"Mayo Clin Proc"},{"key":"2978_CR19","unstructured":"Real world data Co., Ltd. (2025) RWD claims database. https:\/\/rwdata.co.jp\/about\/. Accessed 3 Aug 2025."},{"key":"2978_CR20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/pds.5494","volume":"31","author":"H Ihira","year":"2022","unstructured":"Ihira H, Goto A, Yamagishi K et al (2022) Validity of claims data for identifying cancer incidence in the Japan public health center-based prospective study for the next generation. Pharmacoepidemiol Drug Saf 31:972\u2013982. https:\/\/doi.org\/10.1002\/pds.5494","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2978_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol 26:141\u2013148. https:\/\/doi.org\/10.1093\/annonc\/mdu472","journal-title":"Ann Oncol"},{"key":"2978_CR22","doi-asserted-by":"publisher","first-page":"175883592412419","DOI":"10.1177\/17588359241241972","volume":"16","author":"CH Maeng","year":"2024","unstructured":"Maeng CH, Kim H, Kim M (2024) Time interval between surgery and adjuvant chemotherapy in patients with gastric cancer after gastrectomy: a population-based cohort study using a nationwide claim database. Ther Adv Med Oncol 16:17588359241241972. https:\/\/doi.org\/10.1177\/17588359241241972","journal-title":"Ther Adv Med Oncol"},{"key":"2978_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0227256","volume":"15","author":"CH Bartlett","year":"2020","unstructured":"Bartlett CH, Mardekian J, Cotter MJ et al (2020) Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. PLoS ONE 15:1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0227256","journal-title":"PLoS ONE"},{"key":"2978_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.19.0001","volume":"3","author":"SD Griffith","year":"2019","unstructured":"Griffith SD, Miksad RA, Calkins G et al (2019) Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non\u2013small-cell lung cancer data set. JCO Clin Cancer Inform 3:1\u201313. https:\/\/doi.org\/10.1200\/CCI.19.0001","journal-title":"JCO Clin Cancer Inform"},{"key":"2978_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/ases.13039","volume":"15","author":"T Yoneyama","year":"2022","unstructured":"Yoneyama T, Nakashima M, Takeuchi M et al (2022) Comparison of laparoscopic and open inguinal hernia repair in adults: a retrospective cohort study using a medical claims database. Asian J Endosc Surg 15:513\u2013523. https:\/\/doi.org\/10.1111\/ases.13039","journal-title":"Asian J Endosc Surg"},{"key":"2978_CR26","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM (2019) Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 367:l5657. https:\/\/doi.org\/10.1136\/bmj.l5657","journal-title":"BMJ"},{"key":"2978_CR27","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","volume":"147","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147:W163\u2013W194. https:\/\/doi.org\/10.7326\/0003-4819-147-8-200710160-00010-w1","journal-title":"Ann Intern Med"},{"key":"2978_CR28","doi-asserted-by":"publisher","first-page":"e1501","DOI":"10.1093\/oncolo\/oyae190","volume":"29","author":"X Wang","year":"2024","unstructured":"Wang X, Allen MJ, Espin-Garcia O et al (2024) Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy. Oncologist 29:e1501\u2013e1510. https:\/\/doi.org\/10.1093\/oncolo\/oyae190","journal-title":"Oncologist"},{"key":"2978_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/jjco\/hyx044","volume":"47","author":"A Takashima","year":"2017","unstructured":"Takashima A, Iizumi S, Boku N (2017) Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world. Jpn J Clin Oncol 47:583\u2013589. https:\/\/doi.org\/10.1093\/jjco\/hyx044","journal-title":"Jpn J Clin Oncol"},{"key":"2978_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00432-015-2075-2","volume":"142","author":"KW Lee","year":"2016","unstructured":"Lee KW, Lee JH, Kim JW et al (2016) Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer. J Cancer Res Clin Oncol 142:687\u2013697. https:\/\/doi.org\/10.1007\/s00432-015-2075-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"2978_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","volume":"7","author":"PS Hall","year":"2021","unstructured":"Hall PS, Swinson D, Cairns DA et al (2021) Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial. JAMA Oncol 7:869\u2013877. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0848","journal-title":"JAMA Oncol"},{"key":"2978_CR32","doi-asserted-by":"publisher","first-page":"101431","DOI":"10.1016\/j.clinre.2020.03.029","volume":"45","author":"LJ Palmieri","year":"2021","unstructured":"Palmieri LJ, Dubreuil O, Bachet JB et al (2021) Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: a multicenter prospective AGEO study. Clin Res Hepatol Gastroenterol 45:101431. https:\/\/doi.org\/10.1016\/j.clinre.2020.03.029","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2978_CR33","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/bjc.2015.452","volume":"114","author":"T Janowitz","year":"2016","unstructured":"Janowitz T, Thuss-Patience P, Marshall A et al (2016) Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data. Br J Cancer 114:381\u2013387. https:\/\/doi.org\/10.1038\/bjc.2015.452","journal-title":"Br J Cancer"},{"key":"2978_CR34","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s00520-024-09035-8","volume":"32","author":"Y Sun","year":"2024","unstructured":"Sun Y, Wang Y, Chen G et al (2024) The evolving landscape of antiemetic prophylaxis for chemotherapy\u2011induced nausea and vomiting: inspiration from cisplatin-based antiemetic and non-antiemetic trials. Support Care Cancer 32:822. https:\/\/doi.org\/10.1007\/s00520-024-09035-8","journal-title":"Support Care Cancer"},{"key":"2978_CR35","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1200\/JCO.21.02377","volume":"40","author":"JM Unger","year":"2022","unstructured":"Unger JM, Vaidya R, Albain KS et al (2022) Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials. J Clin Oncol 40:1474\u20131486. https:\/\/doi.org\/10.1200\/JCO.21.02377","journal-title":"J Clin Oncol"},{"key":"2978_CR36","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12885-023-11720-6","volume":"23","author":"M Nakashima","year":"2023","unstructured":"Nakashima M, Li K, Chen Q et al (2023) Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study. BMC Cancer 23:1268. https:\/\/doi.org\/10.1186\/s12885-023-11720-6","journal-title":"BMC Cancer"},{"key":"2978_CR37","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","volume":"33","author":"T Yoshino","year":"2015","unstructured":"Yoshino T, Komatsu Y, Yamada Y et al (2015) Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Investig New Drugs 33:740\u2013750. https:\/\/doi.org\/10.1007\/s10637-014-0154-x","journal-title":"Investig New Drugs"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02978-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02978-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02978-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:14:13Z","timestamp":1774415653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02978-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2978"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02978-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koji Kawakami has received research funds from AstraZeneca, Eisai Co., Ltd., Kyowa Kirin Co., Ltd., OMRON Corporation, and Toppan Inc.; consulting fees from Advanced Medical Care Inc., JMDC Inc., LEBER Inc., Ubicom Holdings, Inc., Santen Pharmaceutical Co., Ltd., and Shin Nippon Biomedical Laboratories Ltd.; executive compensation from Cancer Intelligence Care Systems, Inc. and Mytreya Inc.; honoraria from Kyoto University Original Co., Ltd., Pharma Business Academy, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., and SANSHO Co., Ltd; and held stock in Real World Data Co., Ltd. Satomi Yoshida has received a consulting fee from TOYOTA Konpon Research Institute, Inc. Yoko M. Nakao has been employed by the Department of Digital Health and Epidemiology, an Industry-Academia Collaboration Course supported by Eisai Co., Ltd., and Kyowa Kirin Co., Ltd.; and received a research grant from Bayer, outside of this work. Ryuya Yamamoto declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration of 1964 and later versions. Approval was obtained from the Ethics Committee of the Graduate School of Medicine, Kyoto University (approval number: R4051). The need for informed consent for participation was waived because the study was based on anonymized claims data. The study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}